Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Management of Palpable Pediatric Breast Masses With Ultrasound Characteristics of Fibroadenoma: A More Conservative Approach.

Omar L, Gleason MK, Pfeifer CM, Sharma P, Kwon JK.

AJR Am J Roentgenol. 2019 Feb;212(2):450-455. doi: 10.2214/AJR.17.19482. Epub 2018 Nov 26.

PMID:
30476459
2.

Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells.

Schmohl JU, Gleason MK, Dougherty PR, Miller JS, Vallera DA.

Target Oncol. 2016 Jun;11(3):353-61. doi: 10.1007/s11523-015-0391-8.

3.

An exploratory analysis of mitochondrial haplotypes and allogeneic hematopoietic cell transplantation outcomes.

Ross JA, Tolar J, Spector LG, DeFor T, Lund TC, Weisdorf DJ, Langer E, Hooten AJ, Thyagarajan B, Gleason MK, Wagner JE, Robien K, Verneris MR.

Biol Blood Marrow Transplant. 2015 Jan;21(1):81-8. doi: 10.1016/j.bbmt.2014.09.023. Epub 2014 Oct 6.

4.

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, Epling-Burnette PK, Blazar BR, Weiner LM, Weisdorf DJ, Vallera DA, Miller JS.

Blood. 2014 May 8;123(19):3016-26. doi: 10.1182/blood-2013-10-533398. Epub 2014 Mar 20.

5.

Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.

Wiernik A, Foley B, Zhang B, Verneris MR, Warlick E, Gleason MK, Ross JA, Luo X, Weisdorf DJ, Walcheck B, Vallera DA, Miller JS.

Clin Cancer Res. 2013 Jul 15;19(14):3844-55. doi: 10.1158/1078-0432.CCR-13-0505. Epub 2013 May 20.

6.

Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells.

Vallera DA, Zhang B, Gleason MK, Oh S, Weiner LM, Kaufman DS, McCullar V, Miller JS, Verneris MR.

Cancer Biother Radiopharm. 2013 May;28(4):274-82. doi: 10.1089/cbr.2012.1329. Epub 2013 Apr 23.

7.

Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.

Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX, Panoskaltsis-Mortari A, Weiner LM, Vallera DA, Miller JS.

Mol Cancer Ther. 2012 Dec;11(12):2674-84. doi: 10.1158/1535-7163.MCT-12-0692. Epub 2012 Oct 17.

8.

Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9.

Gleason MK, Lenvik TR, McCullar V, Felices M, O'Brien MS, Cooley SA, Verneris MR, Cichocki F, Holman CJ, Panoskaltsis-Mortari A, Niki T, Hirashima M, Blazar BR, Miller JS.

Blood. 2012 Mar 29;119(13):3064-72. doi: 10.1182/blood-2011-06-360321. Epub 2012 Feb 8.

9.

Isolation and characterization of S49 lymphoma cells deficient in beta-adrenergic receptors: relation of receptor number to activation of adenylate cyclase.

Johnson GL, Bourne HR, Gleason MK, Coffino P, Insel PA, Melmon KL.

Mol Pharmacol. 1979 Jan;15(1):16-27. No abstract available.

PMID:
34089
10.
12.
13.

Regulation of phosphate metabolism in Neurospora crassa. Characterization of regulatory mutants.

Lehman JF, Gleason MK, Ahlgren SK, Metzenberg RL.

Genetics. 1973 Sep;75(1):61-73.

Supplemental Content

Loading ...
Support Center